Regression of alveolar echinococcosis after chronic viral hepatitis C treatment with pegylated interferon alpha 2a

Open access

Abstract

We present a case of 53 years old patient with transplanted kidney, chronic hepatitis C and alveolar echinococcosis who was treated with pegylated interferon α which resulted in regression and calcification of Echinococcus multilocularis loculi. Patient had been diagnosed with chronic hepatitis C two years after kidney transplantation. Hepatitis was left untreated because of immunosuppressive treatment and satisfactory graft function. Nine years after transplantation the patient was diagnosed with alveolar echinococcosis and treated with mebendazole 2 × 200 mg daily for 6 months. Cessation of temporary treatment resulted in echinococcosis progression with appearance of secondary loculi and a small ascites after which mebendazole was restarted. Ten years after transplantation, kidney graft failure occurred and the patient was started on hemodialysis in conjunction with pegylated-interferon alpha 2a for treatment of chronic viral hepatitis C. Complete early viral response was observed 3 months after therapy initiation while a follow-up CT scan after 4 months did not document any changes in the number or size of E. multilocularis loculi. A completed course of antiviral therapy resulted in sustained viral response while a subsequent second follow-up CT scan 6 months after cessation of antiviral therapy documented regression and calcification of main E. multilocularis loculi along with resolution of secondary loculi and ascites.

[1] Borošková, Z., Dvorožňáková, E., Ševčíková, Z. (2003): Cellular immune reactions of mice with alveolar echinococcosis after albendazole therapy. Helminthologia, 40(1): 187–194

[2] Bresson-Hadni, S., Vuitton, D. A., Bartholomot, D., Heyd, B., Godart, D., Meyer, J. P., Hrusovsky, S., Becker, M. C., Mantion, G., Lenys, D., Miguet, J. P. (2000): A twenty-year history of alveolar echinococcosis: analysis of a series of 117 patients from eastern France. Eur. J. Gastroenterol. Hepatol., 12(3): 327–336 http://dx.doi.org/10.1097/00042737-200012030-00011

[3] Dražilová, S., Kinčeková, J., Beňa, Ľ., Zachar, M., Švajdler, M., Zavacký, P., Jarčuska, P. (2011): Alveolar echinococcosis in patient after cadaveric kidney transplantation. Helminthologia, 48(4): 229–236. DOI: 10.2478/s11687-011-0032-4 http://dx.doi.org/10.2478/s11687-011-0032-4

[4] Dvorožňáková, E., Hrčková, G., Borošková, Z., Velebný, S., Dubinský, P. (2004): Effect of treatment with free and liposomized albendazole on selected immunological parameters and cyst growth in mice infected with Echinococcus multilocularis. Parasitol. Int., 53(4): 315–325. DOI:10.1016/j.parint.2004.05.001 http://dx.doi.org/10.1016/j.parint.2004.05.001

[5] Dvorožňáková, E., Porubcová, J., Šnábel, V., Fedoročko, P. (2008): Immunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole. Parasitol. Res., 103(4): 919–929. DOI: 10.1007/s00436-008-1077-2 http://dx.doi.org/10.1007/s00436-008-1077-2

[6] Dvorožňáková, E., Porubcová, J., Ševčíková, Z. (2009): Immune response of mice with alveolar echinococcosis to therapy with transfer factor, alone and in combination with albendazole. Parasitol. Res., 105(4): 1067–1076. DOI: 10.1007/s00436-009-1520-z http://dx.doi.org/10.1007/s00436-009-1520-z

[7] Dubinský, P., Svobodová, V., Turčeková, Ľ., Literák, I., Martínek, K., Reiterová, K., Kolářová, L., Klimesš, J., Mrlík, V. (1999): Echinococcus multilocularis in Slovak Republic: The first record in red foxes (Vulpes vulpes). Helminthologia, 36(2): 105–110

[8] Eckert, J., Gemmell, M., Meslin, F., Pawlowski, Z. S. (2001): WHO/OIE manual on echinococcosis in humans and animals: a public health problem of global concern. Paris: World Health Organization/ World Organization for Animal Health: 20–47

[9] Emery, I., Liance, M., Leclerc, C. (1997): Secondary Echinococcus multilocularis infection in A/J mice: delayed metacestode development is associated with Th1 cytokine production. Parasite Immunol., 19(11): 493–503 http://dx.doi.org/10.1046/j.1365-3024.1997.d01-162.x

[10] EASL — European Association for Study of the Liver (2011): EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J. Hepatol., 55(2): 245–264. DOI: 10.1016/j.jhep.2011.02.023 http://dx.doi.org/10.1016/j.jhep.2011.02.023

[11] Godot, V., Harraga, S., Podoprigora, G., Liance, M., Bardonnet, K., Vuitton, D. A. (2003): IFN alpha-2a protects mice against a helminth infection of the liver and modulates immune responses. Gastroenterology, 124(5): 1441–1450. DOI:10.1016/S0016-5085(03)00273-7 http://dx.doi.org/10.1016/S0016-5085(03)00273-7

[12] Jenne, L., Kilwinski, J., Radloff, P., Flick, W., Kern, P. (1998): Clinical efficacy of and immunologic alterations caused by interferon gamma therapy for alveolar echinococcosis. Clin. Infect. Dis., 26(2): 492–494. DOI: 10.1086/516316 http://dx.doi.org/10.1086/516316

[13] Kern, P., Grüner, P., Wahlers, K. (2011): Diagnosis and course of echinococcal disease in the transplant setting. Transpl. Infect. Dis., 13(3): 217–221. DOI: 10.1111/ j.1399-3062.2011.00643.x http://dx.doi.org/10.1111/j.1399-3062.2011.00643.x

[14] Kinčeková J., Auer H., Reiterová K., Dubinský P., Szilágyiová M., Lauko Ľ., Aspöck H. (2001): The first case of autochtonous human alveolar echinococcosis in the Slovak Republic. Mitt. Österr. Ges. Tropenmed. Parasitol., 23: 33–38

[15] Liance, M., Ricard-Blum, S., Emery, I., Houin, R., Vuitton, D. A. (1998): Echinococcus multilocularis infection in mice: in vivo treatment with a low dose of IFN-gamma decreases metacestode growth and liver fibrogenesis. Parasite, 5(3): 231–237

[16] Miterpáková, M., Dubinský, P., Reiterová, K., Stanko, M. (2006): Climate and enviromental factors influencing Echinococcus multilocularis ocurrence in the Slovak Republic. Ann. Agric. Environ. Med., 13(2): 235–442

[17] Porubcová, J., Dvorožňáková, E., Ševčíková, Z. (2007): Immunomodulative effect of glucan and/or glucan supplemented with zinc in albendazole therapy for murine alveolar echinococcosis. Parasitol. Res., 101: 751–760. DOI: 10.10007/s00436-007-0545-4 http://dx.doi.org/10.1007/s00436-007-0545-4

[18] Rigano, R., Profumo, E., Ioppolo, S., Notargiacomo, S., Ortona, E., Teggi, A., Siracusano, A. (1995): Immunological markers indicating the effectiveness of pharmacological treatment in human hydatid disease. Clin. Exp. Immunol., 102: 281–285. DOI: 10.1111/j.1365-2249.1995.tb03778.x http://dx.doi.org/10.1111/j.1365-2249.1995.tb03778.x

[19] Schweiger, A. (2007): Human alveolar echinococcosis after fox population increase, Switzerland. Emerg. Infect. Dis., 13(6): 878–882 DOI: 10.3201/eid1306.061074 http://dx.doi.org/10.3201/eid1306.061074

[20] Vuitton, D. A., Zhang, S. L., Yang, Y., Godot, V., Beurton, I., Mantion, G., Bresson-Hadni, S. (2006): Survival strategy of Echinococcus multilocularis in the human host. Parasitol. Int. 55:S51–S55 http://dx.doi.org/10.1016/j.parint.2005.11.007

[21] Vuitton, D. A., Gottstein, B. (2010). Echinococcus multilocularis and its intermediate host: a model of parasite-host interplay. J. Biomed. Biotechnol., 2010: 1–14 http://dx.doi.org/10.1155/2010/923193

[22] Wéclawiack, H., Kamar, N., Mehrenberger, M., Guilbeau-Frugier, C., Modesto, A., Izopet, J., Ribes, D., Sallusto, F., Rostaing, L. (2008): Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol. Dial. Transplant., 23(3): 1043–1047 http://dx.doi.org/10.1093/ndt/gfm678

Journal Information


IMPACT FACTOR 2018: 0.731
5-year IMPACT FACTOR: 0.634

CiteScore 2018: 0.8

SCImago Journal Rank (SJR) 2018: 0.398
Source Normalized Impact per Paper (SNIP) 2018: 0.554

Target Group researchers in the field of human, veterinary medicine and natural science

Cited By

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 160 119 7
PDF Downloads 65 55 4